EverGlade Insights Blog
Earlier this month the Army Contracting Command published an amendment to solicitation W911QY-20-S-C001 related to Area of Interest 5, oral antiviral therapeutics. This is a procurement solicitation and specifically the USG is looking for direct-acting...
For the past 18 months companies have been confused and frustrated by the shifting USG policies regarding the development of therapeutics as part of the COVID-19 response. BARDA was back and forth as parts of...
The Joint Army Contracting Command and the Joint COVID Response Division (ACC-JCRD) recently published a solicitation seeking Commercial Solutions to decrease US reliance on fragile global supply chains and increase preparedness for future pandemics. The...
Executive Summary BARDA’s suspension of funding for COVID-19 therapeutics risks repeating mistakes of past pandemics as it may cause industry to pull out of the development space, experts say. Industry sources are concerned the Biden...
The DPA Title III program just received an additional $10B in the recovery legislation that was recently passed. The DPA program is administered by the US Air Force and more information can be found here...
Recently we became aware of two new opportunities for federal funding through HHS and DoD. We believe these may present exciting new avenues for companies that work in these areas. First, BARDA just posted two...